Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
834.04
+7.40 (0.90%)
At close: Aug 21, 2026, 4:00 PM EDT
838.10
+4.06 (0.49%)
After-hours: Aug 21, 2026, 7:58 PM EDT
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $4.29B in the quarter ending June 30, 2026, with 16.73% growth. This brings the company's revenue in the last twelve months to $15.53B, up 9.29% year-over-year. In the year 2025, Regeneron Pharmaceuticals had annual revenue of $14.34B with 0.99% growth.
Revenue (ttm)
$15.53B
Revenue Growth
+9.29%
P/S Ratio
5.36
Revenue / Employee
$1,008,092
Employees
15,410
Market Cap
83.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.34B | 140.90M | 0.99% |
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
| Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
| Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
| Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
| Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
| Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
| Dec 31, 2012 | 1.38B | 932.65M | 209.20% |
| Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
| Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
| Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
| Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
| Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
| Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
| Dec 31, 2005 | 66.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vertex Pharmaceuticals | 12.59B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Moderna | 2.23B |
REGN News
- 3 days ago - Regeneron Announces Investor Conference Presentations - GlobeNewsWire
- 3 days ago - US FDA approves Regeneron's rare bone disorder drug - Reuters
- 3 days ago - Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP) - GlobeNewsWire
- 19 days ago - Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg - Business Wire
- 22 days ago - Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation - GlobeNewsWire
- 23 days ago - Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 23 days ago - Regeneron Pharmaceuticals Earnings release: Q2 2026 - Filings
- 23 days ago - Regeneron Pharmaceuticals Quarterly report: Q2 2026 - Filings